By continuing to use the site you agree to our Privacy & Cookies policy

Herceptin combination treatment hailed

A new targeted breast cancer drug can increase the survival time of some hard-to-treat patients by almost six months, research has shown.

Get unlimited access

As a subscriber you will benefit from:

  • Full online and mobile access to news and opinion stories
  • Customised email alerts straight to your inbox (over 30 alerts available)
  • 4,500 practice articles in our archive 
  • Over £500 worth of CPD learning units